STOCK TITAN

ImmunoGen Announces Webcasts of Presentations at Upcoming Virtual Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

WALTHAM, Mass.--()--ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

  • Piper Sandler 32nd Annual Virtual Healthcare Conference
    November 23 at 10:00am ET
  • Evercore ISI Annual HealthCONx Conference
    December 1 at 12:10pm ET

A webcast of each presentation will be accessible through the Investors and Media section of the Company's website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.”

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

Contacts

INVESTOR RELATIONS AND MEDIA
ImmunoGen
Courtney O’Konek
781-895-0600
courtney.okonek@immunogen.com

OR

FTI Consulting
Robert Stanislaro
212-850-5657
robert.stanislaro@fticonsulting.com

ImmunoGen, Inc.

NASDAQ:IMGN

IMGN Rankings

IMGN Latest News

IMGN Stock Data

8.72B
247.85M
0.32%
86.52%
7.38%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Boston

About IMGN

immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.